Dr. Eugene Chan will showcase groundbreaking advances in biomedical diagnostics at the American Association for Clinical Chemistry (AACC) Annual Meeting, highlighting how rHealth technology is turning science fiction into reality.

The DNA Medicine Institute (DMI) is breaking new ground in space health technology. Its rHEALTH X platform is set to deliver non-invasive, comprehensive diagnostics for astronauts—supporting mission success on the International Space Station and beyond.

Our technology isn’t just pushing boundaries — it’s preparing humanity for the next era of space exploration. Through advanced miniaturized sensing platforms built for autonomy and reliability, we are helping NASA enable astronauts to manage their own health on long-duration missions, without dependence on Earth-based laboratories.

Our work in miniaturized medical technology has earned recognition on the world’s most competitive innovation stage. As a finalist in the $10M Qualcomm Tricorder XPRIZE, DMI continues to prove that truly universal, patient-driven diagnostics are not just possible — they are becoming reality. This milestone reflects our commitment to transforming clinical-grade testing into something accessible, portable, and powered by science that works anywhere people need care.

From spaceflight diagnostics to global health competitions, our technologies continue to earn recognition on the world stage. DMI’s rHEALTH® platform has been repeatedly selected by expert panels for its breakthrough potential in democratizing diagnostics — delivering hospital-grade testing in the palm of a hand, anywhere on Earth or beyond it.

Our technology is not only advancing diagnostics — it is shaping the medical standards of tomorrow. The rHEALTH® Sensor continues to earn recognition in leading scientific journals for its role in bringing real-world, precision-guided medicine to patients anywhere, from clinics to remote and extreme environments.